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A
fter some 60 years in research, a few 
months before my final retirement 
(there were a few temporary ones), the time 
has come to reminisce.
My interest in medicine was imprinted 
early on, when, as a child, I was fasci-
nated by the illustrations in an anatomical 
atlas, especially of reproductive organs. In 
my early teens I undertook dissection of 
chickens, of which my mother was toler-
ant not only because the residues could 
subsequently be converted into soup, but 
because she discerned in this activity the 
seed to my further development as a sur-
geon. However, following my encounter 
with Paul de Kruif’s “Microbe Hunters,” 
a romantic description of Robert Koch 
cloning bacteria on slices of boiled potato, 
Paul Ehrlich discovering the Magic Bullet 
and Pasteur attenuating rabies virus for 
vaccination, I became enthralled with 
research. When my father gave me a Zeiss 
microscope for my 15th birthday, I dis-
covered the joy of observing the otherwise 
invisible, and within a few years a room 
in the attic of our Zurich home was trans-
formed into a rudimentary lab in which, 
among others, I studied vital staining by 
acridine orange of the epithelial cells of 
the newt, at that time still indigenous to 
Zurich ponds. This resulted in my first 
publication, in 1953, in the Zeitschrift fuer 
Zellforschung,1 which at that time, believe 
it or not, even paid a honorarium for con-
tributed articles.
Concurrently I studied medicine, 
eventually earned an MD, and even prac-
ticed as substitute for a country doctor in 
Gossau, a village near Zürich. My experi-
ences persuaded me that mankind would 
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be better served if I dedicated myself to 
research and so I went on to acquire a PhD, 
degree in organic chemistry in 1961, work-
ing on curare alkaloids with Paul Karrer 
(Photo 1), and eventually became a post-
doc with Severo Ochoa in the Department 
of Biochemistry, New York University, 
where I worked from 1961 to 1967 on the 
replication of phage Qβ phage, a plus-
strand RNA virus (Photo 2). The major 
achievement, in collaboration with Piet 
Borst, my erstwhile postdoc and lifelong 
friend, was the discovery that the RNA 
replication intermediate was not a double-
stranded RNA as commonly believed, but 
a single-stranded RNA minus strand. The 
clinching experiment was the demonstra-
tion that highly purified minus strands 
(difficult to obtain prior to the advent of 
recombinant DNA technology) were non-
infectious but could serve as templates for 
the cell-free synthesis of infectious plus 
strands by Qβ replicase. The resulting 
paper2 resolved in my favor a long-lasting, 
painful controversy with Sol Spiegelman, 
one of the most imaginative (some would 
say too imaginative) molecular biologists 
of the sixties, who for many years pushed 
the erroneous idea of a direct, plus-to-
plus strand synthesis by Qβ replicase, the 
enzyme he had discovered.
I returned to Zürich in 1967, as 
Director of the newly founded Institute 
of Molecular Biology (Photo 3), and my 
group, building on my work in New York, 
undertook to enzymatically synthesize 
Qβ RNA in a stepwise fashion. We incu-
bated Qβ replicase and template minus 
strand RNA with only three nucleoside 
triphosphates, so that synthesis stopped 
at the site where the missing substrate © 2012 Landes Bioscience.
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was required, separated the enzyme-
template-product from the substrates and 
performed a second round of synthesis, 
this time adding the nucleoside triphos-
phate that had been missing in the first 
round, along with two others. This pro-
cedure, repeated several times, allowed 
the incorporation of 32P-labeled sub-
strates into short, predetermined RNA 
segments, and by nearest neighbor analy-
sis Martin Billeter and his colleagues, 
in 1969, determined the sequence of 
the first 175 nucleotides of Qβ RNA,3 
for a short while the longest published 
sequence. Gratifyingly, Fred Sanger, in 
his Nobel speech, cited our stepwise syn-
thesis as having inspired his plus/minus 
DNA sequencing strategy.
Stepwise synthesis also enabled us to 
insert nucleotide analogs into precise posi-
tions of the Qβ genome, and in 1974 my 
postdoc Richard Flavell was the first to 
generate a site-directed mutation,4 laying 
the groundwork of what I later termed 
reverse genetics, i.e., the procedure of 
modifying genetic material and ascertain-
ing the resulting phenotype, as opposed to 
classical genetics, where a changed phe-
notype is identified and the responsible 
mutation is then tracked down.5
In the course of exploring site-directed 
mutagenesis, we performed a control 
experiment which led us to the startling 
conclusion that a multiply passaged Qβ 
phage population was highly heteroge-
neous with regard to its RNA sequence. 
We concluded that the population was in a 
dynamic equilibrium, with viable mutants 
arising at a high rate (about 10-4 per nucle-
otide and generation) on the one hand, 
and being strongly selected against on the 
other.6 When I presented these results at 
Manfred Eigen’s annual Klosters meeting 
in 1977, he excitedly pointed out that this 
was exactly what he had predicted in his 
theory of quasispecies. Heterogeneity was 
subsequently found for many other virus 
populations and explains how they can 
rapidly acquire resistance against drugs, 
namely by selection of an inherently resis-
tant variant initially present at undetect-
able levels.
In 1974, Tada Taniguchi joined my 
lab as a graduate student and succeeded 
in generating a complete double-stranded 
DNA copy of Qβ RNA, integrated in a 
plasmid vector which, to our surprise and 
delight, when transfected into E. coli gave 
rise to infectious Qβ phage, the first time 
such a feat was achieved,7 enabling the 
application of recombinant DNA technol-
ogy to RNA viruses.
On my return to Zürich in 1967, I had 
also branched out to study Rous sarcoma 
virus replication. At that time, Temin’s 
hypothesis of reverse transcription was still 
held in wide contempt, and I was convinced 
that a search with appropriate techniques, 
of which I considered myself master, would 
yield an RNA minus strand. In the event 
it did not, and by the time I was ready to 
concede that there was less than one minus 
strand per infected cell, the bombshell of 
the 1970 discovery of reverse transcriptase 
by Temin and Baltimore burst over our 
heads. With John Coffin joining us from 
Temin’s lab, our group made several inter-
esting contributions to the field, including 
the first demonstration that RSV RNA 
was synthesized by DNA-dependent RNA 
polymerase II, the mapping of the RSV 
genes8 and the demonstration of terminal 
redundancy of Avian myeloblastosis virus 
RNA.9 Nonetheless, the competition in 
the field had become so strong that I exe-
cuted a strategic redeployment and turned 
to the study of eukaryotic transcription 
and promoter control, one of the chal-
lenges being that no eukaryotic genes had 
yet been cloned.
Richard Flavell and I had, in 1974, 
devised an imaginative strategy, whereby 
Photo 1. Paul Karrer, Professor of chemistry at the university of Zürich. he received the nobel 
Prize in chemistry in 1937 for his structural elucidation of carotenoids, flavins and vitamins A and 
B2; he was my thesis advisor from 1959–1961 and guided my work on curare alkaloids, his last 
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he (back in Amsterdam) would purify the 
globin DNA minus strand from EcoRI-
cleaved, denatured rabbit chromosomal 
DNA by hybridizing it to β globin mRNA 
and recovering the hybrid on an oligo(dT) 
column, while I would pull out the DNA 
plus strand using a dC-elongated globin 
cDNA on an poly(I) Sephadex column 
(Photo 4). On a memorable weekend we 
got together, hybridized our purified prod-
ucts and attempted to clone the dA-dT 
elongated product in pBR322. Alas, we 
obtained no clones and eventually found 
out that our product was highly inhibitory 
to transfection of E. coli, presumably due to 
all the junk we had accumulated along the 
way. With nothing to show for our efforts, 
we decided to at least have some fun at a 
Harden Conference in Wye College. I set 
forth our strategy; and when I got to the 
point of explaining how I was purifying 
the globin DNA plus strand, Richard, 
on cue, jumped up and exclaimed “Hey, 
I’m purifying the plus strand, you’re sup-
posed to purify the minus strand.” This 
got a good laugh from the audience, but 
our bliss was complete when a breathless 
Nature correspondent approached us and 
asked, “How could you have done such a 
stupid thing?” Unfortunately, she failed to 
get her report published.
We did, however, put some of the tech-
nology to good use. Peter Curtis used 
dC-elongated globin cDNA to pull out 
10S mature β globin mRNA along with 
what proved to be a 15S β globin RNA 
precursor from globin-producing Friend 
cells. We tried to determine whether the 
sequences present in the precursor but not 
in the mRNA were at its 5′ or 3′ end, but 
did not consider that they might be in the 
middle and thus missed discovering the 
large globin intron.
In 1977, at a Gordon Conference, I 
learned a lot about interferon from Peter 
Lengyel, in particular that induction of 
interferon (IFN) mRNA synthesis was 
very rapid, within hours of exposure to 
virus. I thought that studying the inter-
feron gene promoter would be of great 
interest, but at that time not only was 
eukaryotic gene cloning in its infancy, 
but interferon itself had not been purified, 
antibodies to it were not available, and it 
could only be quantified by a laborious 
bioassay. Luckily, Paula Pitha had two 
years earlier shown that poly(A) RNA 
from virus-induced cells, when injected 
into Xenopus oocytes caused synthesis 
and secretion of biologically active inter-
feron, and this experimental tool sug-
gested to me a novel cloning strategy for 
IFN cDNA. We would prepare a bank of 
5,000 individual E. coli clones contain-
ing cDNA plasmids from interferon-pro-
ducing cells, pool them in groups of 500 
clones, fix the plasmid DNA from the 
pools to membranes, hybridize mRNA 
from interferon-producing cells to them, 
elute the RNA, inject it into Xenopus 
oocytes and assay for secreted interferon. 
If a pool gave a positive result, the constit-
uent clones would be assembled in smaller 
groups, and so on, until a positive clone 
was identified.
Photo 2. severo ochoa. While Professor of Biochemistry at the new York university school of Medicine, he discovered polynucleotide phosphory-
lase, which enabled the synthesis of polyribonucleotides, and earned him a share of the nobel Prize in Physiology or Medicine in 1959. his interest in 
biosynthesis of rnA led to my Qβ phage project, which i pursued in his Department from 1961–1967. here, from left to right, Piet Borst (later Director 
of the netherlands cancer institute), severo ochoa, myself, Martin Billeter (later Professor of Molecular Biology at the university of Zürich) and roy 
Burdon (to become chair of Molecular Biology at strathclyde university). in the foreground the wooden mallet with which frozen Qβ-infected E. coli 
paste was reduced to thawable fragments, and on the table the scheme for Qβ rnA replication that emerged from our work. new York, 1964.© 2012 Landes Bioscience.
Do not distribute.
100  Prion  Volume 6 issue 2
At this point I would like to digress 
and survey the biotech landscape in 1977. 
The first biotech company aiming at the 
production of human proteins in bacte-
ria was Genentech, founded by Swanson 
and Boyer in 1976. By 1977, Genentech 
expressed somatostatin in E. coli and the 
meagerly funded company gained an 
investment of $400,000 from INCO, 
the International Nickel Company. 
Genentech’s early success whetted INCO’s 
appetite for biotech ventures and in Spring 
1977 two INCO emissaries persuaded me 
to co-found a biotech company, later to be 
called Biogen, along with Wally Gilbert, 
Phil Sharp, Ken Murray and a number of 
other European molecular biologists and 
some venture capitalists.
Because Biogen could not afford to set 
up its own laboratory, I and other scien-
tific board members undertook projects, 
fully funded by Biogen in our own labs. 
My project proposal was for the cloning 
and expression of interferon cDNA. While 
I was quite confident that we would suc-
ceed in the cloning, there was no way of 
knowing at the time if biologically active 
eukaryotic protein could be produced 
in  E. coli. It was only a year later that 
Genentech reported expression of human 
growth hormone in E. coli.
The reorientation of the IFN project 
toward a commercial objective entailed 
a switch from mouse to human IFN and 
my collaboration with Peter Lengyel was 
postponed in favor of a collaboration with 
Kari Cantell in Helsinki, who was produc-
ing crude IFN preparations from batches 
of virus-infected leukocytes pooled from 
90,000 blood donors. Tada Taniguchi, 
and sometimes I, extracted poly(A) RNA 
from his “used” leukocytes and cloned the 
cDNA in E. coli. In 1978 Tada accepted a 
position at the Cancer Institute in Tokyo 
with the directive to clone interferon! We 
agreed that we in Zürich would work on 
“leukocyte interferon” while Tada would 
undertake the cloning of “fibroblast inter-
feron” in Tokyo.
In the meantime developments within 
Biogen had become critical, the company 
was running out of money and was techni-
cally bankrupt. In the nick of time, Moshe 
Alafi, a venture capitalist and co-founder 
of Biogen, persuaded Schering Plough to 
buy 16% of Biogen for 8 million dollars, 
giving the fledgling company a total value 
of 50 million dollars! Schering thereby 
acquired the rights to three projects, 
among which was IFNα, which I was 
engaged in.
In 1979, Shige Nagata (Photo 5), who 
succeeded Tada in the interferon proj-
ect, began to pick up groups of bacterial 
clones which were scoring positive by the 
Photo 3. the institute of Molecular Biology, 1967. the wooden barrack was erected on the premises of the Veterinary hospital on the irchel, Zürich, 
and housed the newly-founded institute until 1970, when it moved to the eth premises on the hönggerberg. the entire staff, assembled on this cold 
winter morning, comprised (from left to right) our two technicians, ueli sulser and Leposova Andjelkov, Martin Billeter, rose-Marie von rotz, who was 
to remain my indispensable, loyal secretary for the next 30 years, and myself.© 2012 Landes Bioscience.
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hybridization/translation assay and by the 
end of the year he isolated several individ-
ual positive clones, which, on a memorable 
Christmas day, proved to contain inter-
feron activity. Within days we character-
ized the antiviral activity immunologically 
as being human leukocyte interferon, 
prepared a restriction map of the cDNA, 
filed a patent application on January 8, 
1980, announced our achievement at a 
memorable press conference on January 
16 (Photo 6) and followed up with a paper 
in Nature10 describing the first production 
of biologically active human interferon 
in E. coli. A few months after our suc-
cess Genentech and Hoffmann LaRoche, 
in a collaborative effort (which may well 
have made use of a widely circulated pre-
print containing the restriction map) also 
cloned and expressed IFNα; eventually, 
Schering Plough and Biogen shared the 
IFNα market. It is interesting to note that 
the huge interest in interferon had origi-
nally been raised by reports that it was 
effective in cancer treatment. Once inter-
feron was available in sufficient amounts 
to carry out clinical trials on a larger scale 
these hopes were largely dashed; however, 
a rare blood disorder, hairy cell leuke-
mia, could be successfully treated with 
interferon, which in 1986 led to FDA 
approval. After interferon was approved, 
it was tested for other uses and eventu-
ally pegylated IFNα, in combination with 
ribavirin, became the accepted treatment 
of hepatitis C and resulted in a billion dol-
lar market.
Once again, competition by superb 
scientists, including Tom Maniatis, Tada 
Taniguchi and Sydney Pestka, to men-
tion just a few, persuaded me to search 
for greener pastures. In 1982, during 
the International Biochemistry Meeting 
in Perth, I dropped in on a talk by Stan 
Prusiner on scrapie, in which he reported 
the isolation of PrPSc (at that time simply 
called PrP, because he did not yet know 
that there were two forms of the protein), 
from scrapie-infected hamster brain. 
Because he had not found this protein 
in uninfected brain, he suggested that it 
was the infectious agent, and that there 
might be an as yet unknown mechanism 
which would allow this protein to be cop-
ied. I approached him after the talk and 
told him I couldn’t believe that a protein 
could be made without being encoded by 
a mRNA and that I was convinced that 
if one searched for it, it would be found. 
Stan was very open-minded about it and 
we started a collaboration, along with Lee 
Hood, who had sequenced the N-terminus 
of PrP.
I entrusted Bruno Oesch, a young 
post-doc, with preparing and screening a 
cDNA bank of some 150,000 clones from 
scrapie-infected hamster brain with a set 
of degenerate primers prepared by Lee, 
which covered the N-terminus of PrP, and 
Bruno soon found a positive clone which 
contained the complete coding sequence 
of mature PrP. Using the cDNA as probe, 
Photo 4. richard the rabbit. the invention of recombinant DnA tech-
nology in 1972 was followed by a regulatory tsunami aimed at reining 
in the perceived grave dangers of cloning DnA from another species. 
this photograph illustrates the fate suffered by richard flavell while 
attempting to isolate the rabbit globin gene.
Photo 5. shige nagata in action. shige’s untiring efforts led to the first 
isolation of human α interferon cDnA, the cognate chromosomal gene 
family and the expression of biologically active interferon in E. coli. here 
he posed for a photo that appeared in Life magazine. note the state-of-
the-art glass micropipette and the mouth-pipetting technique which 
earned us a tongue-in-cheek reproach from Phil Leder.© 2012 Landes Bioscience.
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we were astonished to find that not only 
scrapie-infected but also normal brain 
DNA contained a PrP gene. Even more 
surprisingly, PrP mRNA was present in 
uninfected brain tissue at the same level as 
infected brain, despite the fact that Stan 
had found PrP only in infected brain. 
The enigma was soon clarified by Stan’s 
group: PrP from infected brain was largely 
proteinase-K-resistant while PrP from 
uninfected brain (PrPC) was completely 
sensitive to the proteinase; because the 
first step in Stan’s purification procedure 
was based on digestion with proteinase K, 
his attempts to purify PrP from uninfected 
brain were unsuccessful. Using a newly 
acquired anti-PrP antibody, Stan found 
that both uninfected and infected brain 
contained PrP, but while the sample from 
infected brain was largely resistant to pro-
teinase K, the PrP signal from uninfected 
brain was wiped out. The resulting semi-
nal Cell paper11 reported that, following 
scrapie infection, PrP was converted into a 
partially proteinase K-resistant form, des-
ignated PrPSc, which might be the infec-
tious agent. Very soon thereafter, in record 
time, a brilliant diploma student, Konrad 
Basler (who years later succeeded me as 
chairman of the Institute), cloned and 
sequenced the chromosomal PrP gene.
Stan’s hypothesis, that the scrapie 
agent was a protein devoid of a nucleic 
acid genome, had from the outset, when 
he published his seminal Science paper in 
1982, been greeted with scorn and antago-
nism. Much of the outrage was elicited by 
his naming the scrapie agent “prion,” for 
“proteinaceous infectious particles” on the 
basis of what was considered very prelimi-
nary evidence. Years later, John Hardy con-
gratulated Stan on inventing the term prion 
because in it Prusiner’s name would reso-
nate for all times. He added that should he 
ever discover a particle causing Alzheimer 
disease he would call it a hardon…
At the time, the prevailing view was 
the scrapie agent contained a nucleic acid 
and was a virus, albeit an unusual one 
in view of its long incubation time and 
its resistance to sterilization, and was for 
many years termed “slow virus.” Stan’s lab 
provided several potent genetic arguments 
that indeed PrPSc was the major if not 
only component of the infectious agent, 
including the demonstration that the spe-
cies barrier for prions could be overcome 
by introducing the PrP gene of the prion 
donor into the recipient and that familial 
Creutzfeldt-Jakob disease was linked to a 
mutation in the PrP gene.
In the late eighties it occurred to me 
that if we could eliminate PrP from the 
mouse it should become resistant to scra-
pie and incapable of replicating the agent. 
One of my very talented colleagues, Michel 
Aguet, using the techniques developed by 
Capecchi, Evans and Smithies, generated 
homozygous PrP knockout mice and we 
Photo 6. cloning gold rush. Biogen called a press conference to announce that we had cloned and expressed human α interferon. rather than garner-
ing applause, i was criticized by both the press and my colleagues for participating in a commercial endeavor while employed by the university. A few 
years later many of my critical colleagues were following my example.© 2012 Landes Bioscience.
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were astonished to find that they devel-
oped normally and were healthy. This was 
one of the first instances where the knock-
out of a mammalian gene had no readily 
discernable consequences and it earned 
the mouse a cover portrait in Nature.12 
We inoculated the knockout mice with 
massive doses of prions; months passed 
excruciatingly slowly, but gratifyingly the 
mice remained healthy and failed to prop-
agate prion infectivity, showing that PrP 
is essential for generating the infectious 
agent and providing impressive support 
for the “protein only” hypothesis. The 
PrP knockout mouse was the first instance 
of an animal genetically engineered to 
be resistant to an infectious disease. We 
published these results in Cell in 1993,13 
and considering that the work had been 
conceived and performed in its entirety 
in Zürich I did not include Stan among 
the authors. This decision regrettably led 
to the end of our long-standing friendship.
While I lost—and missed—the asso-
ciation with Stan, I gained a collaboration 
with an enthusiastic young neuropatholo-
gist, Adriano Aguzzi. We enjoyed many 
years of frictionless and rewarding col-
laborations, and when, in 1999, I retired 
from the University of Zürich (Photo 7) 
to pursue a post-professorial Fellowship in 
John Collinge’s lab in London, Adriano 
developed a meteoric career which rapidly 
propelled him to the Directorship of the 
Neuropathology Institute and led to his 
anointment as the Swiss “Mr Prion.”
In London I took advantage of John’s 
generous hospitality and an MRC grant 
to build up a small group. I had come to 
the conclusion that the classical bioassay 
for prions, which consumed vast numbers 
of mice and took more than half a year 
to execute, was not an appropriate tool 
for an aging scientist. With Peter Kloehn 
I developed a cell-based assay for prions, 
the “standard scrapie cell assay,” which 
took only 12 days to complete, was far 
more accurate than the bioassay, allowed 
partial robotization and a throughput of 
hundreds of samples per week.14
In the fall of 2003, I was surprised 
by a phone call from Richard Lerner, 
then President of the Scripps Research 
Institute in La Jolla, California inquiring 
whether I would be interested in head-
ing a new Scripps institute to be estab-
lished in Florida. By December I agreed 
to accept the position offered, which by 
then had shrunk to chairmanship of a 
department but provided very gener-
ous support. For some time I commuted 
between Florida and London, winding 
up the work in John’s Prion Unit and 
building up a group in the temporary lab 
space made available by Florida Atlantic 
University in Boca Raton. An enterpris-
ing postdoc, Sukhi Mahal, who had 
worked with me in London, accompa-
nied me to Florida and developed the cell 
panel assay, which allowed the character-
ization of prion strains by their ability to 
infect four cell lines, as assessed by the 
standard scrapie cell assay. This enabled 
us to discover that prions were subject to 
mutation and selection in cultured cells, 
Photo 7. grillfest. the happy look on my face testifies to the satisfac-
tion of my life-long addiction to the famed swiss “Kalbsbratwurst,” 
here at the annual “grillfest” on the eth campus on the höngger-
berg, summer 1998.
Figure 1. genealogy in science. successful scientists are frequently the 
scientific offspring of other successful scientists, however, if there is a 
genetic component to nobel predisposition (crown-like symbol), it is likely 
recessive. only a few of my hundred-odd scientific offspring are listed (in 
alphabetical order), several of whom have outclassed me.© 2012 Landes Bioscience.
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and resulted in what will have been my 
last Science paper.15
As my eightieth birthday approached, 
I decided to retire while my departure 
still elicits expressions of regret rather 
than relief. I have noted that it is more 
rewarding to train students than to pub-
lish papers, because the half-life of a paper 
is three years, while that of a scientist is 
30 years. Happily, I leave behind more 
than 100 former students, many of whom 
surpassed me in their accomplishments 
and some of whom may perpetuate the sci-
entific tradition I inherited from my own 
teachers (Fig. 1).
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